Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Plasma cell 3Myeloid 2Lymphoid 2Dermatologic 1CNS 1

Conditions

Leukemia 2Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 35Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16venetoclax 14thymoglobulin 14Granulocyte Colony-Stimulating Factor 14Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Blood Component Removal × Myeloid × Clear all
NCT02433483 2017-11-01

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

St. Jude Children's Research Hospital

Phase 2 Terminated
4 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00499889 2012-04-23

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

M.D. Anderson Cancer Center

Phase 2 Terminated
42 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡